Tonvasca Capsules 2/10 mg

 

Category: Pharmaceutical

Exhibitor: ORIENT PHARMA CO., LTD.

Booth No: M426

 

Characteristic

 

Tonvasca (pitavastatin/ezetimibe fixed-dose combination) offers distinctive clinical value and product advantages. Its innovative micro-pellet capsule formulation is suitable for patients requiring tube feeding or those with swallowing difficulties. Utilizing a non-CYP450 metabolic pathway, it minimizes the risk of drug-drug interactions, making it particularly appropriate for patients with multiple comorbidities and complex medication regimens. Clinically, Tonvasca achieves over 50% LDL-C reduction and has a relatively lower incidence of new-onset diabetes, offering an optimal balance of lipid-lowering efficacy and metabolic safety.

Developed over eight years, Tonvasca underwent rigorous multinational, multi-center clinical trials in Taiwan, New Zealand, and Australia. Manufactured locally and launched internationally, it exemplifies Taiwan's innovation in pharmaceutical R&D. Its scientific merit and breakthrough design were recognized with the 2023 National Pharmaceutical Technology Research Development Award, affirming its position as a milestone in locally developed therapeutics.

 

Other Products

 

• 

  Jakop Extended Release Tablet

• 

  Zulitor Tablets 4mg

• 

  Methydur Sustained Release Capsules

• 

  Vancover Capsules 125 mg

• 

  Rivastigmine Patch 9.5mg/24hrs

• 

  Trokendi XR extended release capsules 25mg, 50mg, 100mg

 

 

 

Back